A-FABP Concentration Is More Strongly Associated with Cardiometabolic Risk Factors and the Occurrence of Metabolic Syndrome in Premenopausal Than in Postmenopausal Middle-Aged Women
Table 5
Diagnostic utility of A-FABP for predicting cardiometabolic risk factors and metabolic syndrome.
PRE AUC (95% CI)
POST AUC (95% CI)
PRE versus POST
Cutoff
PRE Sensitivity/specificity (%)
POST Sensitivity/specificity (%)
MetS
0.90 (0.84–0.96)
0.56 (0.43–0.69)
<0.001
27.0 30.0
88/87 78/87
75/40 62/52
HOMA-IR ≥ 3.4
0.85 (0.76–0.94)
0.61 (0.40–0.81)
0.04
27.0 30.0
80/79 80/81
88/36 75/49
HDL-C < 50
0.85 (0.75–0.95)
0.73 (0.57–0.89)
0.25
27.0 35.0
73/94 53/100
82/39 73/60
TC/HDL-C ≥ 4
0.84 (0.76–0.92)
0.53 (0.40–0.66)
<0.001
21.0 30.0
92/65 61/89
84/18 74/40
TG/HDL-C ≥ 1.3
0.75 (0.67–0.86)
0.64 (0.50–0.78)
0.22
21.0 30.0
88/55 50/80
100/21 71/51
CRP ≥ 1
0.74 (0.64–0.84)
0.71 (0.59–0.83)
0.73
21.0 30.0
68/67 36/91
91/31 66/69
Elevated BP (≥130/≥85 mmHg)!
0.76 (0.66–0.85)
0.52 (0.38–0.65)
0.03
27.0 35.0
67/82 44/90
69/31 49/56
BMI ≥ 30
0.83 (0.75–0.93)
0.79 (0.68–0.89)
0.51
21.0 30.0
86/70 52/96
78/72 91/31
Area under the curve (AUC), confidence interval (CI), blood pressure (BP), premenopausal women (PRE), and postmenopausal women (POST). Elevated BP or hypertension treatment.
